COVID-19 vaccination: Why extend the interval between doses?

J Assoc Med Microbiol Infect Dis Can

National Advisory Committee on Immunization, Ottawa, Ontario, Canada.

Published: June 2021

On March 3, 2021, faced with ongoing morbidity and mortality from coronavirus disease 2019 (COVID-19) and insufficient supplies of authorized, available vaccines against COVID-19 in Canada, the National Advisory Committee on Immunization (NACI) issued a strong recommendation to allow for an extended interval between vaccine doses to maximize the number of people protected as quickly as possible. NACI's recommendation was released in the form of a rapid response because of the urgency of the situation and was based on a review of the evidence; principles of immunology; historical experience with vaccines; modelling studies; and consideration of ethics, equity, feasibility, and acceptability. Since then, many questions and concerns have been raised. This article aims to provide further explanation of the rationale for the decision and prepare health care providers with information they need as they support their patients in the vaccination rollout.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608698PMC
http://dx.doi.org/10.3138/jammi-2021-0323DOI Listing

Publication Analysis

Top Keywords

covid-19 vaccination
4
vaccination extend
4
extend interval
4
interval doses?
4
doses? march
4
march 2021
4
2021 faced
4
faced ongoing
4
ongoing morbidity
4
morbidity mortality
4

Similar Publications

Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco.

BMC Infect Dis

December 2024

Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco.

To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.

View Article and Find Full Text PDF

Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population.

View Article and Find Full Text PDF

Long-term multi-systemic complications following SARS-CoV-2 Omicron and Delta infection in children: a retrospective cohort study.

Clin Microbiol Infect

December 2024

National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.

Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!